LiverLearning®: 2019 Career Development Workshop

The Career Development Workshop is designed for hepatologists in the early career stage. Participants will explore how to maximize career opportunities in basic and clinical research, and will discuss potential sources of research funding for each pathway. They will also review an array of career pathways in both academic and community practice, and possible rewards and challenges hepatologists may encounter.

LiverLearning®: Liver Cell Biology in Hepatic Diseases SIG: Regenerative Medicine and the Bio-Artificial Liver

Recent advances in liver bio-engineering have led to multiple in vitro culture systems that duplicate many complex cell-cell interactions of the intact liver. This symposium will highlight recent advances in this field, show current use of ex-vivo, 3D multicellular culture systems as probes of liver function and disease and update the progress toward the generation of the bio-artificial liver.

LiverLearning®: Hepatitis C SIG: Improving the Care Continuum for Chronic HCV Infection in 2019

Review steps to develop programs to eradicate HCV in the U.S. at this program. Speakers will address the current state of screening, novel models to engage more patients into therapy and the current state of access to HCV therapeutics, including generics. They will contrast U.S. efforts to eradicate HCV with programs from around the world.

Farnesoid X Receptor Agonism, Acetyl‐Coenzyme A Carboxylase Inhibition, and Back Translation of Clinically Observed Endpoints of De Novo Lipogenesis in a Murine NASH Model

Berangere Gapp, Marie Jourdain, Pauline Bringer, Benjamin Kueng, Delphine Weber, Arnaud Osmont, Stefan Zurbruegg, Judith Knehr, Rocco Falchetto, Guglielmo Roma, William Dietrich, Reginald Valdez, Nicolau Beckmann, Florian Nigsch, Arun J. Sanyal, Iwona Ksiazek – 8 November 2019 – A promising approach for the treatment of nonalcoholic steatohepatitis (NASH) is the inhibition of enhanced hepatic de novo lipogenesis (DNL), which is the synthesis of fatty acids from nonlipid sources.

Designing Clinical Trials in Pediatric Nonalcoholic Steatohepatitis: Tips for Patient Selection and Appropriate Endpoints

Naim Alkhouri, Rohit Kohli, Ariel E. Feldstein – 8 November 2019 – Nonalcoholic fatty liver disease (NAFLD) is common in children and may progress to nonalcoholic steatohepatitis (NASH), advanced fibrosis, and even cirrhosis in childhood or early adulthood, indicating the need for pharmacologic treatment in this age group. Multiple trials are evaluating different therapeutic targets for NASH with fibrosis in adults, and the U.S.

Subscribe to